Search
for
Sort by
Research 181–210 of 1000+
- A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Alopecia areata
- Tofacitinib for the treatment of lichen planopilaris: A case series
- Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata
- Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
- Tofacitinib for the treatment of alopecia areata in preadolescent children
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata
- Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Excellent response to tofacitinib treatment in a patient with alopecia universalis
- Rethinking the classification of alopecia areata
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
- Unraveling the secret life of the hair follicle: from fungi to innovative hair loss therapies
- Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
- Topical tofacitinib for the treatment of alopecia areata affecting facial hair
- Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
- Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata